1438 related articles for article (PubMed ID: 27543837)
21. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
Younossi ZM; Yilmaz Y; Yu ML; Wai-Sun Wong V; Fernandez MC; Isakov VA; Duseja AK; Mendez-Sanchez N; Eguchi Y; Bugianesi E; Burra P; George J; Fan JG; Papatheodoridis GV; Chan WK; Alswat K; Saeed HS; Singal AK; Romero-Gomez M; Gordon SC; Roberts SK; El Kassas M; Kugelmas M; Ong JP; Alqahtani S; Ziayee M; Lam B; Younossi I; Racila A; Henry L; Stepanova M;
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2296-2306.e6. PubMed ID: 34768009
[TBL] [Abstract][Full Text] [Related]
22. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
[TBL] [Abstract][Full Text] [Related]
23. Nonalcoholic fatty liver disease burden - Switzerland 2018-2030.
Goossens N; Bellentani S; Cerny A; Dufour JF; Jornayvaz FR; Mertens J; Moriggia A; Muellhaupt B; Negro F; Razavi H; Semela D; Estes C
Swiss Med Wkly; 2019 Dec; 149():w20152. PubMed ID: 31846507
[TBL] [Abstract][Full Text] [Related]
24. Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
Terai S; Buchanan-Hughes A; Ng A; Lee IH; Hasegawa K
J Gastroenterol; 2021 Mar; 56(3):274-284. PubMed ID: 33496858
[TBL] [Abstract][Full Text] [Related]
25. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Younossi Z; Tacke F; Arrese M; Chander Sharma B; Mostafa I; Bugianesi E; Wai-Sun Wong V; Yilmaz Y; George J; Fan J; Vos MB
Hepatology; 2019 Jun; 69(6):2672-2682. PubMed ID: 30179269
[TBL] [Abstract][Full Text] [Related]
26. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements.
Johansen P; Howard D; Bishop R; Moreno SI; Buchholtz K
Pharmacoeconomics; 2020 May; 38(5):485-497. PubMed ID: 31919793
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
Satapathy SK; Sanyal AJ
Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
[TBL] [Abstract][Full Text] [Related]
28. Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Younossi ZM; Henry L; Bush H; Mishra A
Clin Liver Dis; 2018 Feb; 22(1):1-10. PubMed ID: 29128049
[TBL] [Abstract][Full Text] [Related]
29. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis.
Schattenberg JM; Lazarus JV; Newsome PN; Serfaty L; Aghemo A; Augustin S; Tsochatzis E; de Ledinghen V; Bugianesi E; Romero-Gomez M; Bantel H; Ryder SD; Boursier J; Leroy V; Crespo J; Castera L; Floros L; Atella V; Mestre-Ferrandiz J; Elliott R; Kautz A; Morgan A; Hartmanis S; Vasudevan S; Pezzullo L; Trylesinski A; Cure S; Higgins V; Ratziu V
Liver Int; 2021 Jun; 41(6):1227-1242. PubMed ID: 33590598
[TBL] [Abstract][Full Text] [Related]
30. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
[TBL] [Abstract][Full Text] [Related]
31. Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany.
Canbay A; Kachru N; Haas JS; Meise D; Ozbay AB; Sowa JP
Ann Transl Med; 2021 Apr; 9(8):615. PubMed ID: 33987313
[TBL] [Abstract][Full Text] [Related]
32. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients.
C Gordon S; Fraysse J; Li S; Ozbay AB; Wong RJ
Am J Gastroenterol; 2020 Apr; 115(4):562-574. PubMed ID: 31833859
[TBL] [Abstract][Full Text] [Related]
33. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis.
Rich NE; Oji S; Mufti AR; Browning JD; Parikh ND; Odewole M; Mayo H; Singal AG
Clin Gastroenterol Hepatol; 2018 Feb; 16(2):198-210.e2. PubMed ID: 28970148
[TBL] [Abstract][Full Text] [Related]
34. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases.
Wong RJ; Kachru N; Martinez DJ; Moynihan M; Ozbay AB; Gordon SC
J Clin Gastroenterol; 2021 Nov-Dec 01; 55(10):891-902. PubMed ID: 32815873
[TBL] [Abstract][Full Text] [Related]
35. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
Roeb E; Geier A
Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
[TBL] [Abstract][Full Text] [Related]
36. Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA.
Nguyen AL; Park H; Nguyen P; Sheen E; Kim YA; Nguyen MH
Dig Dis Sci; 2019 Mar; 64(3):698-707. PubMed ID: 30327963
[TBL] [Abstract][Full Text] [Related]
37. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
38. Non-alcoholic fatty liver disease: A growing public health problem in Turkey.
Kaya E; Yılmaz Y
Turk J Gastroenterol; 2019 Oct; 30(10):865-871. PubMed ID: 31258135
[TBL] [Abstract][Full Text] [Related]
39. Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis.
Sayiner M; Otgonsuren M; Cable R; Younossi I; Afendy M; Golabi P; Henry L; Younossi ZM
J Clin Gastroenterol; 2017 Mar; 51(3):254-260. PubMed ID: 27332747
[TBL] [Abstract][Full Text] [Related]
40. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey.
Wong RJ; Liu B; Bhuket T
Aliment Pharmacol Ther; 2017 Nov; 46(10):974-980. PubMed ID: 28914448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
